Exact Sciences Corp (EXAS.OQ)
EXAS.OQ on NASDAQ Stock Exchange Capital Market
67.44USD
16 Oct 2018
67.44USD
16 Oct 2018
Change (% chg)
$1.67 (+2.54%)
$1.67 (+2.54%)
Prev Close
$65.77
$65.77
Open
$66.62
$66.62
Day's High
$67.90
$67.90
Day's Low
$65.33
$65.33
Volume
533,261
533,261
Avg. Vol
724,791
724,791
52-wk High
$81.22
$81.22
52-wk Low
$37.39
$37.39
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
Kevin Conroy |
52 | 2014 | Chairman of the Board, President, Chief Executive Officer |
Jeffrey Elliott |
40 | 2016 | Chief Financial Officer |
Mark Stenhouse |
51 | 2018 | President, Cologuard |
Graham Lidgard |
69 | 2009 | Senior Vice President, Chief Scientific Officer |
D. Scott Coward |
53 | 2015 | Senior Vice President, General Counsel, Secretary |
- UPDATE 1-Exact Sciences surges after marketing deal with Pfizer for cancer test
- Exact Sciences signs marketing deal with Pfizer for cancer test
- UPDATE 1-American Cancer Society recommends earlier colorectal cancer screening
- American Cancer Society recommends earlier colorectal cancer screening
- BRIEF-Exact Sciences Says CEO Kevin T. Conroy's 2017 Total Compensation Was $13.3 Million